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Abstract
Fibromyalgia is a chronic, musculoskeletal pain condition that
predominately affects women. Although fibromyalgia is common
and associated with substantial morbidity and disability, there are
no US Food and Drug Administration-approved treatments.
However, progress has been made in identifying pharmacological
and non-pharmacological treatments for fibromyalgia. Recent
pharmacological treatment studies have focused on selective
serotonin and norepinephrine reuptake inhibitors, which enhance
serotonin and norepinephrine neurotransmission in the descending
pain pathways and lack many of the adverse side effects
associated with tricyclic medications. Promising results have also
been reported for medications that bind to the α2δ subunit of
voltage-gated calcium channels, resulting in decreased calcium
influx at nerve terminals and subsequent reduction in the release of
several neurotransmitters thought to play a role in pain processing.
There is also evidence to support exercise, cognitive behavioral
therapy, education, and social support in the management of
fibromyalgia. It is likely that many patients would benefit from
combinations of pharmacological and non-pharmacological
treatments, but more study is needed.
Introduction
This review focuses on recent randomized, controlled studies
of pharmacological and non-pharmacological therapies for
fibromyalgia. Clinical recommendations for the management
of fibromyalgia will be based on the available evidence from
these trials. Although much work remains, progress has been
made in identifying potentially efficacious treatments for
fibromyalgia. The treatment of fibromyalgia is a rapidly
growing area of research, and it is likely that treatment
options will continue to expand for patients with fibromyalgia.
Although fibromyalgia causes substantial morbidity and
disability, there are no US Food and Drug Administration
(FDA)-approved or European Medicines Agency (EMEA)-
approved treatments. Strategies that are being pursued to
develop better treatments for fibromyalgia include the
development of large, multicenter, well-controlled clinical
trials to test the efficacy of a variety of therapies. The results
of the clinical trials will help to identify which patients might
benefit from a particular treatment, whether that treatment
approach is pharmacological, non-pharmacological or a
combination of different therapies. The ultimate goal of
fibromyalgia treatment is to develop an individualized
treatment approach that takes into account the nature of the
patient’s fibromyalgia symptoms and their severity, the level of
function and stressors, and the presence of medical and
psychiatric comorbidity.
New developments in the pharmacological
treatment of fibromyalgia
Serotonin and norepinephrine reuptake inhibitors
There is emerging evidence that fibromyalgia is associated
with aberrant central nervous system processing of pain
[1-4]. Although the American College of Rheumatology
criteria for fibromyalgia [5] require tenderness in 11 out of 18
discrete regions, patients with fibromyalgia have increased
sensitivity to pressure pain throughout the body. Fibromyalgia
patients often develop an increased response to painful
stimuli (hyperalgesia) and experience pain from normally non-
noxious stimuli (allodynia) [6]. Both hyperalgesia and
allodynia reflect an enhanced central nervous system
processing of painful stimuli that is characteristic of central
sensitization [7].
Serotonergic and noradrenergic neurons are implicated in the
mediation of endogenous pain inhibitory mechanisms through
the descending inhibitory pain pathways in the brain and
spinal cord [8-10]. Dysfunction in serotonin and nor-
epinephrine in these pain inhibitory pathways may contribute
to the central sensitization and hyperexcitability of the spinal
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and supraspinal pain transmitting pathways and manifest as
persistent pain associated with fibromyalgia and some other
chronic pain conditions [11-15]. Medications that increase
the activity of serotonin and norepinephrine may correct a
functional deficit of serotonin and norepinephrine neuro-
transmission in these descending inhibitory pain pathways
and, therefore, help reduce pain.
Systematic reviews
Three recent meta-analyses of fibromyalgia pharmacological
trials assessed the efficacy of medications that inhibit the
reuptake of serotonin and/or norepinephrine. The first meta-
analysis [16] assessed nine placebo-controlled trials of the
cyclic drugs that inhibit the reuptake of both serotonin and
norepinephrine, including the tricyclics amitriptyline [17-20],
dothiepin, which is structurally similar to amitriptyline and
doxepin [21], cyclobenzaprine [18,22-24], which possesses
structural and pharmacological properties of other tricyclics
[25], clomipramine [26], and the tetracyclic maprotiline [26].
Seven outcome measures were assessed, including: the
patients’ self-ratings of pain, stiffness, fatigue and sleep; the
patient and the physician global assessment of improvement;
and tender points. The largest effect was found in measures
of sleep quality, with more modest changes in tender point
measures and stiffness. Thus, the most consistent improve-
ment could be attributed to the sedative properties of these
medications.
The results of another meta-analysis of randomized, placebo-
controlled studies of cyclobenzaprine was consistent with the
Arnold and colleagues [16] meta-analysis. Cyclobenzaprine
treatment resulted in moderate improvement in sleep, modest
improvement in pain, and no improvement in fatigue or tender
points [27].
A third meta-analysis of antidepressants in the treatment of
fibromyalgia [28] evaluated 13 trials of antidepressants, most
of which studied the cyclic drugs amitriptyline [17-20,26,
29-32], clomipramine [26], and maprotiline [26]. The meta-
analysis also included trials of the selective serotonin reuptake
inhibitors (SSRIs) fluoxetine [20,33] and citalopram [34], as
well as a reversible inhibitor of the monoamine oxidase-A
enzyme, moclobemide [29], and the dietary supplement S-
adenosylmethionine [35,36]. Outcome measures included the
number of tender points, and patients’ self-ratings of pain,
sleep, fatigue, and overall well being. The pooled results
showed a significant symptomatic benefit of antidepressants
that was moderate for sleep, overall well being, and pain
severity, and mild for fatigue and number of tender points. The
magnitude of benefit was similar to that found in the Arnold
and colleagues [16] meta-analysis. Because only three trials of
SSRIs were included in the meta-analysis, it was not possible
to assess the relative efficacy of SSRIs.
The trials of SSRIs in fibromyalgia have shown mixed results,
suggesting that medications with selective serotonin effects
are less consistent than those with dual effects on
norepinephrine and serotonin in the relief of pain associated
with fibromyalgia. Citalopram, which has the highest
selectivity for the serotonin reuptake transporters among the
SSRIs, was not effective for the treatment of fibromyalgia in
two small controlled studies [33,37]. On the other hand, the
SSRIs fluoxetine and paroxetine CR, which may have
additional effects on norepinephrine at adequate doses
[38,39], have been shown to be effective for fibromyalgia in
recent studies [40,41].
Although the meta-analyses indicated that the overall effect of
the cyclic drugs on most symptoms of fibromyalgia was
modest, possibly related to the low doses that were typically
studied, tricyclics continue to be frequently recommended for
the treatment of patients with fibromyalgia [42]. Furthermore,
even at low doses, many patients experience problems with
the safety and tolerability of these medications related to their
anticholinergic, antiadrenergic, antihistaminergic, and quinidine-
like effects [43].
Recently, fibromyalgia trials have focused on new selective
serotonin and norepinephrine reuptake inhibitors (SNRIs),
which are potent dual reuptake inhibitors but, unlike the
tricyclics, do not interact with adrenergic, cholinergic or
histaminergic receptors, or sodium channels, and, therefore,
lack many side effects of tricyclics. Preliminary, open trials of
the SNRI venlafaxine were promising [44,45], but one study,
a six-week, randomized, placebo-controlled, double-blind trial
of a fixed, low dose of venlafaxine (75 mg/day) [46], found
that venlafaxine improved some but not all measures of pain.
The short duration of this trial and low dose of venlafaxine
may explain the discrepant results. To date, two randomized,
placebo-controlled studies of the SNRI duloxetine and one
study of the SNRI milnacipran in the treatment of fibromyalgia
have been published, and are described below.
Duloxetine
Duloxetine, a new, potent SNRI with dual reuptake inhibition of
serotonin and norepinephrine over the entire clinically relevant
dose range [47], is a safe, tolerable, and effective antidepres-
sant [48-50] that also significantly reduces painful physical
symptoms associated with major depressive disorder [51]. In
non-depressed patients with diabetes, duloxetine effectively
reduces diabetic peripheral neuropathic pain [52,53],
supporting an analgesic effect of duloxetine that is independent
of its effects on mood. Duloxetine is currently indicated by the
FDA for the treatment of major depressive disorder in adults
and diabetic peripheral neuropathic pain in adults [54].
The first study of duloxetine in fibromyalgia was a randomized,
placebo-controlled, double-blind, parallel-group, multi-site,
12-week monotherapy study of duloxetine titrated to 60 mg
twice a day (BID) that included 207 patients with fibromyalgia
with or without current major depressive disorder [55]. Co-
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questionnaire (FIQ) total score and pain score [56]. The FIQ
is a self-report instrument in which patients rate their overall
symptoms and function over the previous week. Duloxetine-
treated patients compared with placebo-treated patients
improved significantly more on the FIQ total score, but not on
the FIQ pain score. However, duloxetine-treated patients had
significantly greater improvement in secondary measures of
pain, including the Brief Pain Inventory (short form) [57]
average pain severity score, which measured pain over the
past 24 hours from 0 (no pain) to 10 (pain as bad as you can
imagine), and the average pain interference score, which
assessed interference from 0 (does not interfere) to 10
(completely interferes) with general activity, mood, walking
ability, normal work, relations with other people, sleep, and
enjoyment of life. Duloxetine-treated patients compared with
patients on placebo also experienced significant improvement
in tender point number and mean tender point pain
thresholds that were assessed using a Fischer dolorimeter
[58] applied to the 18 tender point sites defined by the
American College of Rheumatology criteria. Other secondary
measures that significantly improved in the duloxetine-treated
group compared with the placebo group included the FIQ
stiffness score, Clinical Global Impression of Severity scale
[59], and the Patient Global Assessment of Improvement
scale. Quality of life measures that significantly improved in
the duloxetine group compared with the placebo group
included the Quality of Life in Depression Scale total score
[60], the Sheehan Disability Scale total score [61], and the
Medical Outcomes Study Short Form 36 (SF-36) physical
subscore and scores for bodily pain, general health perception,
mental health, physical functioning, and vitality [62].
Significantly more duloxetine-treated female patients (30.3%)
had a clinically meaningful (≥50%) decrease in the FIQ pain
score compared with placebo-treated female patients
(16.5%). In addition, the Brief Pain Inventory average pain
severity score decreased by ≥50% in significantly more
duloxetine-treated women (30%) than women on placebo
(16%). However, duloxetine-treated male patients failed to
significantly improve on any efficacy measure. The reasons for
the sex differences in response to duloxetine are unclear, but
may be related to the small male subgroup (23 (11%) of 207
patients), or to possible sex differences in fibromyalgia that
affect treatment response.
The duloxetine trial was one of the first fibromyalgia clinical
trials to assess baseline psychiatric comorbidity using a
structured psychiatric clinical interview and to include
patients with and without current major depressive disorder in
order to evaluate the impact of major depressive disorder on
the response to treatment with duloxetine. Of importance is
that duloxetine reduced pain severity regardless of the
presence or absence of major depressive disorder. In
addition, the treatment effect of duloxetine on significant pain
reduction in female patients was independent of the effect on
depressive or anxiety symptoms. Therefore, the effect of
duloxetine on the reduction of pain associated with fibro-
myalgia appears to be independent of its effect on mood.
Duloxetine was well tolerated, and there was no significant
difference in the number of patients who discontinued due to
adverse events. Duloxetine-treated patients reported insomnia,
dry mouth, and constipation significantly more frequently than
placebo-treated patients. Most treatment-emergent adverse
events were of mild or moderate severity.
The second, randomized, placebo-controlled, double-blind,
parallel-group, multi-site, 12-week study of duloxetine
monotherapy in fibromyalgia tested the safety and efficacy of
both 60 mg BID and a lower dose of 60 mg once a day (QD)
in 354 women with fibromyalgia with or without current major
depressive disorder [63]. This study included only women to
confirm the results of the first duloxetine trial in which women,
but not men, responded significantly to duloxetine compared
with the same sex placebo-treated patients on efficacy
measures. The primary outcome measure was pain severity
as measured by the Brief Pain Inventory (short form) average
pain severity score (score range 0 to 10). Compared with the
placebo group, the duloxetine 60 mg QD group and the
duloxetine 60 mg BID group experienced significantly greater
improvement in the Brief Pain Inventory average pain severity
score, beginning at week 1 and continuing through week 12.
Significantly more patients treated with duloxetine 60 mg QD
(41%) and duloxetine 60 mg BID (41%) compared with
placebo (23%) had a ≥50% reduction in the Brief Pain
Inventory average pain severity score. Compared with
placebo, duloxetine 60 mg QD or duloxetine 60 mg BID
resulted in significantly greater improvement in the remaining
Brief Pain Inventory pain severity and interference scores, and
other secondary outcomes, including the FIQ, Clinical Global
Impression of Severity, and the Patient Global Impression of
Improvement. Consistent with the first duloxetine study,
several quality of life measures significantly improved in both
duloxetine groups compared with the placebo group,
including the Quality of Life in Depression Scale total score,
the Sheehan Disability Scale total score, and the SF-36
mental subscore, bodily pain, mental health, role limit
emotional, role limit physical, and vitality. There were no
significant differences between duloxetine 60 mg QD and
duloxetine 60 mg BID treatment groups in efficacy outcomes.
However, only the duloxetine 60 mg BID dose, compared
with placebo, significantly improved the tender point
assessments. This suggests that the higher dose may be
necessary to improve pressure pain thresholds, which have
been found to be less responsive to treatment in previous
fibromyalgia trials using tricyclics [16,28]. As in the first study
of duloxetine, the treatment effect of duloxetine on pain
reduction was independent of the effect on mood and the
presence of major depressive disorder.
The most frequent side effect in patients in the duloxetine
60 mg QD and 60 mg BID groups was nausea, and side
Available online http://arthritis-research.com/content/8/4/212effects were generally mild to moderate in severity for most
patients. Significantly more patients in the duloxetine 60 mg
BID group than the placebo group discontinued treatment
due to adverse events. This finding differs from the previous
duloxetine trial of 60 mg BID in which there were no
differences between treatment groups in discontinuation due
to treatment-emergent adverse events. The difference
between the studies might be explained by the slower
titration of duloxetine in the first study, in which duloxetine
was titrated from a starting dose of 20 mg QD to 60 mg BID
over 2 weeks. In the second study, patients were started on
60 mg QD and titrated to 60 mg BID over just three days.
This suggests that some patients would benefit from a lower
duloxetine starting dose and slower titration.
The results of both duloxetine studies in fibromyalgia provide
evidence that duloxetine 60 mg QD and 60 mg BID for up to
12 weeks are safe and effective in the treatment of fibro-
myalgia in women with or without major depressive disorder.
Milnacipran
Milnacipran is another selective SNRI that has been approved
for treatment of depression since 1997 in parts of Europe,
Asia, and elsewhere, but is currently unavailable in the US.
Milnacipran is a dual serotonin and norepinephrine reuptake
inhibitor within its therapeutic dose range and also exerts mild
N-methyl-D-aspartate (NMDA) inhibition [64].
In a double-blind, placebo-controlled, multicenter trial, 125
patients (98% women) with fibromyalgia were randomized to
receive placebo or milnacipran monotherapy for 4 weeks of
dose escalation to the maximally tolerated dose followed by
8 weeks of stable dose (25 to 200 mg/day) [65]. The study
evaluated the efficacy and safety of two different dosing
regimens of milnacipran (QD versus BID) for the treatment of
fibromyalgia. The primary outcome measure was based on
change of average daily pain scores recorded on an
electronic diary (e-diary), comparing the two-week baseline
period to endpoint (last two weeks on treatment). The
majority of milnacipran-treated patients, 92% of completers
on the BID regimen and 81% on the QD regimen, titrated to
the highest daily dose (200 mg). Although the primary
outcome measure of daily e-diary pain scores did not
significantly improve in either patients on BID milnacipran or
those on the QD regime compared to placebo, patients
treated with milnacipran on a BID schedule experienced
significant improvement in the weekly e-diary pain scores,
paper pain scores, and the McGill Pain Questionnaire
present pain intensity score [66] compared to those on
placebo. Furthermore, significantly more patients receiving
milnacipran BID (37%) reported a reduction in the weekly
average pain scores by 50% or more, compared with 14% of
patients in the placebo group. Milnacipran-treated patients on
the QD schedule did not exhibit the same degree of
improvement in pain, suggesting that dosing frequency is
important in the use of milnacipran for pain associated with
fibromyalgia. The QD regime may have resulted in inadequate
drug levels of milnacipran and less effective pain relief by the
end of the day because of milnacipran’s short half-life of 6 to
8 hours. Both milnacipran groups (QD and BID dosing),
compared with the placebo-treated patients, had significantly
greater improvement in other secondary measures, including
the patient global impression of change score, and the
physical function and ‘days felt good’ subscales of the FIQ.
The BID milnacipran-treated group, compared to patients on
placebo, also had significant improvement in the FIQ scores
for pain, fatigue, and morning stiffness.
Milnacipran was generally well tolerated and most adverse
events were rated as mild or moderate in severity. Overall,
14.4% of patients discontinued the study due to adverse
events, including 7 (13.7%) from the milnacipran BID group,
10 (21.7%) from the milnacipran QD group, and 1 (3.6%)
from the placebo-treated group. Headache and gastro-
intestinal complaints (nausea, abdominal pain, gastrointestinal
upset, and constipation) were the most frequent reasons for
early discontinuation. Other reasons included orthostatic
dizziness, exacerbation of hypertension, depression, lethargy,
increased sweating, and hot flashes. The QD group
experienced a higher incidence of adverse events than the
BID group, suggesting that the QD dose was not as well
tolerated as BID dosing.
As in the duloxetine trials, patients were evaluated for
psychiatric comorbidity and those with and without current
major depressive disorder were included. Unlike the results of
the duloxetine trials in which both depressed and non-
depressed patients responded similarly to duloxetine,
statistically greater improvement in pain reduction was seen
in non-depressed patients versus depressed patients treated
with milnacipran. Although this finding needs to be replicated
in a larger clinical trial, the positive response in non-
depressed patients suggests that, like duloxetine, the pain
relieving effects of milnacipran do not occur only through
improvement in mood.
Summary of serotonin and norepinephrine reuptake inhibitors
The earlier evidence from studies of cyclic agents and the
new studies of selective SNRIs support the efficacy of
medications with dual effects on serotonin and nor-
epinephrine in fibromyalgia. In recent trials, the SNRIs were
found to improve pain and other important symptom domains
of fibromyalgia in addition to improving function, quality of life,
and global well-being (Table 1). Most studies of tricyclic
drugs used low doses, an approach that may have been
influenced by concern about the undesirable side effects of
the tricyclics. Recent studies of selective SNRIs have
assessed a wider range of doses, which have been well
tolerated by most patients and effective in reducing many of
the symptoms and impact of fibromyalgia. Fibromyalgia trials
have not directly compared selective SNRIs with tricyclics,
and it is unknown whether the selective SNRIs are more
Arthritis Research & Therapy    Vol 8 No 4 Arnold
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However, the new selective SNRIs provide an alternative for
patients who have tolerability or safety concerns related to
the side effects of tricyclics.
Alpha 2 delta ligands
In parallel with the development of selective SNRIs for
fibromyalgia, another approach is being explored using
medications that bind to the α2δ subunit of voltage-gated
calcium channels, resulting in decreased calcium influx at
nerve terminals and subsequent reduction in the release of
several neurotransmitters thought to play a role in pain
processing, such as glutamate and substance P [10,67].
Pregabalin is an alpha 2 delta ligand that has analgesic,
anxiolytic-like, and anticonvulsant activity and is approved by
the FDA for the treatment in adults of diabetic peripheral
neuropathic pain, postherpetic neuralgia, and adjunctive
therapy in partial onset seizures [54].
A multicenter, randomized, placebo-controlled, 8 week,
monotherapy trial tested the safety and efficacy of pregabalin
150, 300, or 450 mg/day administered 3 times daily in equal
doses in 529 patients with fibromyalgia (91% female) [67].
The primary outcome measure was a daily paper pain diary in
which patients selected a number on a numerical scale from
0 (no pain) to 10 (worst possible pain) that best described
their pain during the past 24 hours. The outcomes that
responded significantly to pregabalin 450 mg/day compared
with placebo were the mean weekly pain (diary) score, the
Short-form McGill Pain Questionnaire total score and VAS
pain score [68], daily sleep (diary) score (a 0 to 10 numerical
scale on the quality of sleep), the Medical Outcomes Study
Sleep scale [69], Multidimensional Assessment of Fatigue
[70], Clinical/Patient Global Impression of Change, and
SF-36 domains of social functioning, bodily pain, vitality, and
general health perception. A significantly larger proportion of
patients receiving pregabalin 450 mg/day (28.9%) exper-
Available online http://arthritis-research.com/content/8/4/212
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Table 1
Randomized, double-blind, placebo-controlled trials of serotonin and norepinephrine reuptake inhibitors and alpha 2 delta ligands
in fibromyalgia
Drug  Study design  Duration  Outcomes that significantly improved 
Study (mg/day) (no. of patients) (weeks) with treatment over placebo
SNRI
Arnold et al. [55] Duloxetine (120) Duloxetine v  12 Primary measure: FIQ total score (FIQ pain score 
placebo, parallel  improved in women only)
(207)
Secondary measures: FIQ stiffness scores, BPI pain 
severity and interference from pain, tender points, 
CGI-S, PGI-I, QLDS, SDS, SF-36 physical subscore 
and bodily pain, general health perception, mental 
health, physical function, vitality scores
Gendreau et al. [65] Milnacipran  Milnacipran v  12 Secondary measures: Pain (weekly e-diary pain score, 
(up to 200) placebo, parallel  paper daily and weekly scores, present pain score), 
(125) patient global impression of change, FIQ physical 
function, days felt good, pain, fatigue, and morning 
stiffness scores 
Arnold et al. [63] Duloxetine  Duloxetine v  12 Primary measure: BPI average pain severity
(60 and 120) placebo, parallel 
(354) Secondary measures: BPI interference from pain, FIQ 
total score, tender points (120 mg only), CGI-S, PGI-I, 
QLDS, SDS, SF-36 mental subscore and scores for 
social function (60 mg only), physical function (120 mg 
only), bodily pain, mental health, role limit emotional 
and physical, and vitality
Alpha 2 delta 
Crofford et al. [67] Pregabalin  Pregabalin v placebo,  8 Primary measure: mean daily pain score (daily diaries) 
(150, 300,  parallel (529) (450 mg only)
and 450)
Secondary measures: sleep quality diary (300 mg, 
450 mg), MAF global fatigue (300 mg, 450 mg), 
patient and clinician global impression of change 
(300 mg, 450 mg), SF-36 general health (150 mg, 
300 mg, 450 mg), vitality (450 mg), bodily pain 
(450mg), social functioning (450 mg)
BPI, Brief Pain Inventory; CGI-S, Clinician global impression of severity; FIQ, Fibromyalgia Impact Questionnaire; MAF, Multidimensional
Assessment of Fatigue; PGI-I, Patient global impression of improvement; QLDS, Quality of Life in Depression Scale; SDS, Sheehan Disability
Scale; SF-36, Medical Outcomes Study Short Form.ienced a ≥50% reduction in the pain (diary) score compared
with the placebo group (13.2%). Compared with placebo,
pregabalin 300 mg/day significantly improved sleep as
measured by both the daily sleep diary and the Medical
Outcomes Study Sleep scale, significantly improved fatigue,
the SF-36 domain of general health perception, and the global
change assessments by the patients and clinicians. Patients
taking 150 mg/day of pregabalin also reported improved sleep
on the Medical Outcomes Study Sleep Scale and improvement
in general health perception compared with placebo.
Pregabalin was generally well tolerated and most adverse
events were mild or moderate in severity. The most common
side effects were dizziness and somnolence, which tended to
be dose related across the pregabalin groups. Few patients
withdrew due to these symptoms. The median duration of
dizziness in patients who did not withdraw from the study was
15 days in those taking 450 mg/day of pregabalin; the mean
duration for somnolence was 18 days in the same group.
Other side effects that were more frequent in the pregabalin
group included abnormal thinking, euphoria, dry mouth,
peripheral edema, and weight gain.
Unlike the duloxetine and milnacipran studies, patients in the
pregabalin trial were not evaluated for the presence of
comorbid psychiatric disorders. However, anxiety and
depressive symptoms were assessed using the Hospital
Anxiety and Depression Scale [71], and the mean baseline
scores were mild. There were no significant changes in the
Hospital Anxiety and Depression Scale anxiety or depressive
scores at endpoint from those at baseline, which suggests
that the improvement in pain was probably independent of
any improvement in anxiety or depressive symptoms.
Another recent study examined the effects of pregabalin
compared with alprazolam and placebo on aspects of sleep
in 24 healthy adult volunteers who received pregabalin
150 mg three times a day, alprazolam 1 mg three times a
day, or placebo three times a day for three days [72].
Compared with placebo, pregabalin significantly increased
slow-wave sleep both as a proportion of the total sleep
period and the duration of stage 4 sleep. Alprazolam, on the
other hand, significantly reduced slow-wave sleep. Both
pregabalin and alprazolam produced significant reduction in
sleep-onset latency compared with placebo. Pregabalin also
significantly reduced the number of awakenings of more than
1 minute in duration. Pregabalin’s enhancement of slow-
wave sleep could be very important in many patients with
fibromyalgia in whom there is a reduction in slow-wave
sleep.
In summary, the results of the first published, randomized,
controlled trial of an alpha 2 delta ligand, pregabalin, in
fibromyalgia demonstrated that pregabalin monotherapy
reduced pain and improved other key symptom domains of
fibromyalgia, such as fatigue and sleep. In addition,
pregabalin treatment was associated with improvement in
health-related quality of life and global assessments.
Sedative-hypnotic medication
Although there continues to be debate about the role of sleep
disturbance in the pathogenesis of fibromyalgia, many
patients with fibromyalgia experience disrupted or non-
restorative sleep and benefit from treatment. A few controlled
studies have examined sedative hypnotics in the treatment of
fibromyalgia. The short-acting non-benzodiazepine sedatives
zolpidem and zopiclone improved sleep in patients with
fibromyalgia but did not improve pain, limiting their usefulness
in fibromyalgia as monotherapy [73-75]. While the combina-
tion of alprazolam and ibuprofen was somewhat beneficial in
a pilot trial of fibromyalgia [76], another study found no
significant benefit of another benzodiazepine, bromazepan,
over placebo in the treatment of fibromyalgia [77].
Gamma-hydroxybutyrate (GHB) is a precursor of gamma-
aminobutyric acid (GABA) with marked sedative properties.
Sodium oxybate, the sodium salt of GHB, was granted an
Orphan Drug Status by the FDA for the treatment of
cataplexy and excessive daytime sleepiness in patients with
narcolepsy, which was classified as an orphan (rare) disease
[54]. A preliminary, 4 week, double-blind, placebo-controlled
crossover trial of 24 women with fibromyalgia suggested that
sodium oxybate reduced symptoms of pain and fatigue,
decreased the tender point index, and increased slow-wave
sleep and decreased alpha intrusion on polysomnography
[78]. A recently completed 8 week study of sodium oxybate
monotherapy evaluated 4.5 g or 6 g per day taken in two
equally divided doses (bedtime and 2.5 to 4 hours later) in
188 patients with fibromyalgia [79]. The primary outcome, a
composite of changes from baseline in three co-primary, self-
report measures (pain visual analog scale from electronic
diaries, the FIQ, and the patient global assessment) improved
significantly with both dosages of sodium oxybate compared
to placebo. Both dosages were also significantly superior to
placebo in improvement of sleep quality; the tender point
count improved only in the higher sodium oxybate dose
compared to placebo. The direct relationship between
change in pain and insomnia suggested that the improvement
in pain was related to improved sleep. Sodium oxybate was
well tolerated; the most common side effects were nausea
and dizziness.
Despite the results of this proof-of-principle study, GHB’s
abuse potential and its use in cases of date rape [80] will
likely limit the usefulness of sodium oxybate in patients with
fibromyalgia. A recent study evaluating the relative abuse
liability of hypnotic drugs reported that GHB was associated
with a high likelihood of abuse. Furthermore, GHB, along with
pentobarbital and methaqualone, were more likely to be lethal
at supratherapeutic doses than any of the other hypnotics
[81]. Finally, patients with chronic pain may be especially at
risk for the development of problematic hypnotic use [81].
Arthritis Research & Therapy    Vol 8 No 4 Arnold
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ment of narcolepsy is only available through a Risk Manage-
ment Program that was designed to maximize physician and
patient education about the safe use of the drug and minimize
potential diversion or abuse by limiting distribution through a
central pharmacy. This risk management program has
appeared to be effective in preventing diversion and limiting
abuse in patients with narcolepsy, although the evaluation of
the program is ongoing [82]. It is not clear, however, whether
this program would be effective in the much larger group of
patients (mostly women) with fibromyalgia, who have chronic
pain and frequent psychiatric comorbidities that might make
them more vulnerable to the abuse potential of sodium oxybate.
Safer alternatives for the management of insomnia include
low-dose tricyclic agents, and, more recently, the alpha 2
delta ligand pregabalin or a related compound, gabapentin,
which have sedative properties, improve slow-wave sleep,
and relieve pain [72,83].
Opiates
There is controversy about the use of opiates to manage the
pain associated with fibromyalgia because of the abuse
potential of these agents and the lack of data supporting their
efficacy in fibromyalgia. However, a survey of academic
medical centers in the US reported that about 14% of fibro-
myalgia patients were treated with opiates [84]. A small,
double-blind, placebo-controlled study found that intravenous
administration of morphine in nine patients with fibromyalgia
did not result in a reduction of pain intensity [85]. A recent,
four year, non-randomized study of opiates in fibromyalgia
discovered that the fibromyalgia patients taking opiates did
not experience significant improvement in pain at the four
year follow-up compared with baseline, and reported
increased depression in the last two years of the study [86].
These results suggest that opiates may not have a role in the
long-term management of fibromyalgia. In addition, there is
emerging evidence that opioid-induced hyperalgesia might
limit the usefulness of opioids in controlling chronic pain [87].
Although the mechanisms by which opioids promote pain are
not completely understood, recent animal studies suggest
that chronic use of opioids induces neuroadaptive changes
mediated, in part, through the NK-1 receptor, that result in
enhancement of nociceptive input [88]. These results raise
the possibility that prolonged treatment of pain with opiates
may actually cause unintentional harm to patients [88].
Tramadol is a novel analgesic with weak agonist activity at the
mu opiate receptor combined with dual serotonin and
norepinephrine reuptake inhibition that may exert anti-
nociceptive effects within both the ascending and descen-
ding pain pathways. Three controlled studies have evaluated
the efficacy of tramadol in fibromyalgia. The first small study
used a double-blind crossover design to compare single-
dose intravenous tramadol 100 mg with placebo in 12
patients with fibromyalgia. Patients receiving tramadol
experienced a 20.6% reduction in pain compared with an
increase of 19.8% of pain in the placebo group [89]. The
second study of tramadol began with a three week, open-
label phase of tramadol 50 to 400 mg/day followed by a six-
week double-blind phase in which only patients who tolerated
tramadol and perceived benefit were enrolled [90]. The
primary measure of efficacy was the time to exit from the
double-blind phase because of inadequate pain relief. One
hundred patients with fibromyalgia were enrolled in the open-
label phase; 69% tolerated and perceived benefit from
tramadol and were randomized to tramadol or placebo.
Significantly fewer patients on tramadol discontinued during
the double-blind phase because of inadequate pain relief.
This study is limited by the possible unblinding of patients in
the double-blind phase after open-label treatment with
tramadol. Finally, a multicenter, double-blind, randomized,
placebo-controlled, 91 day study examined the efficacy of the
combination of tramadol (37.5 mg) and acetaminophen
(325 mg) in 315 patients with fibromyalgia. Patients taking
tramadol and acetaminophen (4 ± 1.8 tablets per day) were
significantly more likely than placebo-treated subjects to
continue treatment and experience an improvement in pain
and physical function [91]. Treatment emergent adverse
events were reported by significantly more patients in the
tramadol/acetaminophen group (75.6%) than the placebo
group (55.8%). The most common side effects in the
tramadol/acetaminophen group were nausea, dizziness,
somnolence, and constipation. A post hoc analysis of the
data from this trial revealed that the patients who had the
most reduction in pain severity (≥25 mm on the 0 to 100 mm
visual analog scale) from baseline had significantly greater
improvement in health-related quality of life than those with
less reduction in pain. When comparing treatment groups,
improvements in the SF-36 physical functioning, role-
physical, bodily pain, and physical component summary
scores were significantly greater in the tramadol/
acetominophen than the placebo group [92].
Although tramadol is currently marketed as an analgesic
without scheduling under the US Controlled Substances Act,
it is under review for possible control, and it should be used
with caution because of recent reports of classic opioid with-
drawal with discontinuation and dose reduction and
increasing reports of abuse and dependence [93].
Other pharmacological studies in fibromyalgia
Preliminary evidence from randomized, controlled studies
supports the possibility that other pharmacological approaches
hold promise for fibromyalgia, but more study is needed.
Among these possible medications are the 5-HT3 antagonists
(e.g., ondansetron and tropisetron), which have analgesic
effects. A randomized, placebo-controlled, double-blind,
10 day trial in 418 patients with fibromyalgia evaluated the
short-term efficacy of tropisetron at doses of 5 mg/day,
10 mg/day, and 15 mg/day. Significant reduction in pain was
noted only in those patients taking 5 mg/day and 10 mg/day,
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from placebo, suggesting a bell-shaped dose response curve
[94]. Another, recent, randomized, placebo-controlled trial of
21 female fibromyalgia patients evaluated daily intravenous
bolus injections of 5 mg tropisetron for 5 days and found
significant improvement in pain in the tropisetron group
compared to placebo [95]. The presence of 5-HT3 receptors
on both the inhibitory dorsal horn interneurons and the
primary afferent fibers that relay nociceptive information from
peripheral nociceptives to the dorsal horn may explain the
pro- and anti-nociceptive effects of 5-HT3 receptor blockade.
The balance of these opposing effects may be dose-
dependent and contribute to unpredictable results with
tropisetron [96], but more study of longer-term treatment with
5-HT3 antagonists is needed.
Central sensitization, a possible pathogenic mechanism of
the chronic pain associated with fibromyalgia, is mediated, in
part, by the binding of excitatory amino acids (glutamate and
aspartate) to the NMDA receptor. NMDA antagonists may
inhibit or attenuate central sensitization [97] and potentially
reduce pain associated with fibromyalgia. In one clinical
study, 48 female patients with fibromyalgia were treated with
an open-label combination of tramadol 200 mg/day and
increasing doses of dextromethorphan (50 to 200 mg/day),
titrated to therapeutic effect or tolerability. Fifty-eight percent
(28 of 48) responded to the addition of dextromethorphan
and entered a double-blind phase in which the patients were
randomized to dextromethorphan and tramadol or tramadol
and placebo. A Kaplan-Meier drop-out analysis showed that
significantly fewer patients on dextromethorphan and tramadol
discontinued treatment compared with patients on tramadol
alone [98]. More study of NMDA receptor antagonists is
needed before clinical recommendations can be made
regarding the use of these agents. Interestingly, a study
looking at the effects of dextromethorphan on temporal
summation of pain in patients with fibromyalgia compared to
normal controls found that dextromethorphan had similar
effects in both groups on reduction in wind-up from repeated
thermal and mechanical pressure stimulation of the skin.
These results suggest that patients with fibromyalgia do not
have substantially altered NMDA receptor mechanisms and
other mechanisms, such as enhanced descending facilitation,
should be considered for the pain associated with fibro-
myalgia [99].
Finally, pramipexole, a dopamine 3 receptor agonist, was
tested in patients with fibromyalgia in a 14 week, single-
center, randomized, placebo-controlled study in which prami-
pexole was added on to existing pharmacological and non-
pharmacological therapies [100]. The rationale for testing a
dopamine 3 agonist in fibromyalgia is based on evidence that
excessive adrenergic arousal may fragment sleep, and
enhancement of dopaminergic neurotransmission at the D3
receptors in the mesoliombic hippocampus may reduce
expression of arousal and improve sleep. Compared with the
placebo group, those patients receiving pramipexole titrated
over 12 weeks to 4.5 mg every evening had gradual and
significant improvement in pain, fatigue, function, and global
status. A gradual titration of pramipexole was well tolerated;
weight loss and increased anxiety were significantly more
common in patients on pramipexole.
Sleep was not assessed in the study, despite the proposed
role of pramipexole in reducing adrenergic arousal in patients
with fibromyalgia; therefore, the mechanism by which
pramipexole improved the symptoms of fibromyalgia is
unclear. The study was also difficult to interpret because the
participants were taking concomitant medications (about half
on narcotic analgesics) for fibromyalgia.
Limitations of pharmacological treatment studies in
fibromyalgia
The pharmacological treatment studies of fibromyalgia are
limited for several reasons. First, many of the medication trials
were of short duration, and there is a need for more data on
the long-term efficacy of medications in the treatment of
fibromyalgia, a chronic condition. Second, although most
fibromyalgia clinical trials assessed change in the intensity of
pain as the primary outcome, they have inconsistently
evaluated other associated symptoms, such as sleep distur-
bance, fatigue, depression, anxiety, cognition, or function and
health-related quality of life, which reduce the comparability
and clinical applicability of the trials. Third, medication clinical
trials have used dissimilar measures to assess symptom and
functional domains. Fourth, the primary outcome measure of
most recent fibromyalgia trials has been the mean reduction
of pain in the patients receiving a treatment compared with
those receiving placebo. Although this approach provides
information about the overall efficacy of a particular treatment
in reducing pain, it does not determine the proportion of
patients who experience clinically important improvement.
Fifth, there is a lack of consensus about the definition of
clinically meaningful reduction in pain for fibromyalgia clinical
trials. In addition, it is unclear whether improvement in pain
intensity alone should define response to treatment in fibro-
myalgia, which is a syndrome characterized by multiple symp-
toms in addition to pain. Standardized, operationally defined
outcome measures of fibromyalgia activity and improvement
would greatly enhance the comparability, validity, and clinical
applicability of fibromyalgia trials. Sixth, patients with fibro-
myalgia frequently have comorbid disorders that may affect
their response to treatment. Despite evidence of elevated
prevalence rates of mood and anxiety disorders in patients
with fibromyalgia and their possible prognostic significance,
few clinical trials systematically evaluated patients for
comorbid psychiatric disorders. Seventh, most trials excluded
patients with pain from some other disorders, such as
rheumatoid arthritis, inflammatory arthritis or autoimmune
disease, and future trials should examine the efficacy of
medications in these patients. Finally, the majority of patients
studied in the trials were women, which reflects the much
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of the studies may not, therefore, be generalizable to men
with fibromyalgia.
Summary of pharmacological trials in fibromyalgia
Despite the limitations of the pharmacological trials, much
progress has been made in identifying effective medication
treatments for patients with fibromyalgia. Two recent
pharmacological approaches have shown promise in large,
multicenter, randomized, placebo-controlled trials: the SNRIs
duloxetine and milnacipran, and the alpha 2 delta ligand
pregabalin. All three medications reduced pain, the primary
symptom of fibromyalgia, and improved other important
symptom domains, some aspects of function, and global
assessments, as summarized in Table 1. In addition to
efficacy, their safety and tolerability also make them important
options for patients with fibromyalgia. Table 2 outlines the
conclusions that can be drawn from the results of the recent
randomized, placebo-controlled pharmacological trials.
Continued clinical trials of these medications, combinations
of medications, and other drugs with alternative mechanisms
of action are needed to identify effective and FDA-approved
treatments for fibromyalgia.
New developments in the non-
pharmacological treatment of fibromyalgia
Systematic reviews of non-pharmacological modalities
Several systematic reviews of non-pharmacological treat-
ments for fibromyalgia have been published since 1999. The
first review was a meta-analysis of pharmacological and non-
pharmacological treatment studies of fibromyalgia completed
between 1966 and 1996 [102]. Studies of patients with
fibromyalgia were included in the analysis if they had
sufficient statistical information to calculate effect sizes on
the outcome variables of physical status, self-report of fibro-
myalgia symptoms, psychological status, or daily functioning.
The meta-analysis included 33 pharmacological and 16 non-
pharmacological treatment studies. The pharmacological
treatments included: tricyclic agents (tricyclic antidepres-
sants or the muscle relaxant cyclobenzaprine, which is
structurally a tricyclic); S-adenosylmethionine (SAMe); alpra-
zolam; 5-hydroxytryptophan; the SSRIs fluoxetine and citalo-
pram; the non-steroidal anti-inflammatory drugs (NSAIDs)
ibuprofen and naproxen; prednisone; zolpidem; topical cap-
saicin; a combination of malic acid and magnesium hydroxide;
mexiletine (oral lidocaine); a combination of carisoprodol,
paracetamol and caffeine; myanserine; chlormezanone; and
an antidiencephalon immune serum. Non-pharmacological
therapies included exercise, education, cognitive-behavioral
therapy, electroacupuncture, acupuncture, and hypnotherapy.
After combining effects sizes within the two classes of
treatment for each outcome variable, both pharmacological
and non-pharmacological treatments were associated with
improvement in physical status, fibromyalgia symptoms, and
psychological status; only non-pharmacological treatment
improved daily functioning. Furthermore, non-pharmacological
treatment was superior to pharmacological treatment on
fibromyalgia symptoms. However, this meta-analysis was
limited by pooling diverse pharmacological and non-
pharmacological treatments, making it difficult to evaluate
individual treatments, and by including studies that were of
poor methodological quality.
Instead of evaluating non-pharmacological treatments as a
group as was done in the Rossy and colleagues [102] meta-
analysis described above, a subsequent systematic review
focused only on mind-body therapies, which included
autogenic training, relaxation exercises, meditation, cognitive-
behavioral training, hypnosis, guided imagery, biofeedback, or
education [103]. Thirteen randomized or quasi-randomized
controlled trials conducted between 1966 and 1999 were
evaluated with a best-evidence synthesis method that has
been used in Cochrane systematic reviews. There were
several important findings from this review. First, there was
strong evidence that mind-body therapies were more
effective for self-efficacy (a measurement of an individual’s
belief that she or he can cope effectively with a challenging
situation) than waiting list or treatment as usual controls
[104,105]. However, improvements in self-efficacy did not
correspond to improvements in other clinical measures.
Indeed, the results suggested that mind-body therapies were
not consistently better than waiting list or treatment as usual
controls in the modulation of pain or improvement in function.
Second, there was strong evidence that exercise was more
effective than mind-body therapies for short-term improve-
ment in pain intensity or tender point pain threshold and
physical function [106,107]. Third, patients with fibromyalgia
who were also severely depressed did not respond well to
mind-body therapies [104]. Finally, mind-body therapies with
cognitive restructuring and coping components were not
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Table 2
Summary of findings from pharmacological studies in
fibromyalgia
1. Serotonin and norepinephrine reuptake inhibitors improve pain,
other symptom domains, function, quality of life, and global well-
being in patients with fibromyalgia.
2. Selective serotonin and norepinephrine reuptake inhibitors (SNRIs)
offer an alternative to cyclic medications (e.g., tricyclics) that are
associated with safety and tolerability concerns.
3. The effect of SNRIs on reduction in pain associated with
fibromyalgia is independent of their effects on mood.
4. Alpha 2 delta ligands also improve pain, other symptom domains,
function, and global well-being in patients with fibromyalgia.
5. Alpha 2 delta ligands improve slow wave sleep.
6. Drugs associated with high risk of abuse and dependence should
be avoided. Opiates may contribute to hyperalgesia if used
chronically.
7. Although studies are limited, combinations of medications (e.g.,
combination of an SNRI and alpha 2 delta ligand) may be an
option for patients who do not fully respond to a single agent or
who have problems with tolerability at higher doses.significantly better than education or attention controls. For
example, in a controlled study, 131 outpatients with fibro-
myalgia were randomized to one of 3 conditions: a 12
session, combined educational and cognitive group inter-
vention; an attention control condition consisting of group
education plus group discussion; and a waiting list control.
For the sample as a whole, very little improvement was found.
The patients in the attention control condition with group
education and discussion did somewhat better than those in
the combined education and cognitive intervention with
improved pain coping and pain control, although neither
group experienced improvement in pain intensity [105].
Another controlled study of 71 patients with fibromyalgia
evaluated a 10 week behavioral treatment program that con-
sisted of 90 minute weekly group sessions of education,
training in relaxation, behavioral goal setting and activity
pacing, and involvement of a support person to promote
adaptive coping techniques and encourage adherence to the
protocol. Both the behavioral treatment and an education
control that consisted of lectures and group discussion
resulted in significant reductions in depression, self-reported
pain behavior, observed pain behavior, and myalgic scores (a
measure of pressure pain threshold). Pain levels were not
reduced in either condition. Furthermore, the effect of the
behavioral treatment condition was no better than the
education control [108].
Another  recent systematic review of randomized, controlled
trials of several non-pharmacological treatments for fibro-
myalgia completed between 1980 and 2000 assessed
methodological quality according to a set of formal criteria
adapted from other Cochrane systematic reviews [109]. Inter-
ventions tested in the 25 reviewed trials included exercise
therapy, educational intervention, relaxation therapy, cognitive-
behavioral therapy, acupuncture, and forms of hydrotherapy.
Aerobic exercise (nine studies), education (four studies), and
relaxation (four studies) were the most frequently evaluated
interventions. Although there was a lack of strong evidence to
support any single intervention, there was preliminary support
of moderate strength for aerobic exercise. Overall, the
methodological quality of the studies was judged to be fairly
low, mostly as a result of small samples with low mean power
to detect a medium effect. Furthermore, 16 studies had
blinded outcome assessments, but patients were blinded in
only 6 studies. In contrast to the Rossy and colleagues [102]
meta-analysis, which found favorable results for non-
pharmacological therapies when grouped together, at the level
of the specific non-pharmacological modalities assessed in
this review, the evidence supporting their use in fibromyalgia
was inconclusive due to the methodological limitations of
most of the studies.
Finally, a Cochrane review of randomized clinical trials
assessed the effectiveness of multidisciplinary rehabilitation
for patients with fibromyalgia [110]. The multidisciplinary
program was required to consist of a physician’s consul-
tation, in addition to a psychological, social, or vocational
intervention, or a combination of these. Only four randomized,
controlled trials of fibromyalgia conducted between 1966
and 1998 met methodological inclusion criteria, although the
overall quality of these studies was determined to be poor.
Nonetheless, several findings from the review emerged that
were consistent with some of the results from the above
systematic reviews, which included some of the same
studies. First, the effectiveness of aerobic exercise was
neutral compared to stress management in the long-term
treatment of pain, tenderness, or work capacity [107]. This
conclusion differs from the Hadhazy and colleagues review
[103], which focused on the short-term benefits of exercise
among the participants who completed this trial [107].
Second, education combined with physical exercise was
better than education alone in a long-term follow-up study
[104]. Finally, as reviewed above, neither a combined
education and cognitive group intervention nor behavioral
therapy was more effective than education alone
[105,108].
Systematic review of exercise therapy
The use of exercise as a therapy for fibromyalgia received
support in the above reviews of non-pharmacological inter-
ventions. Another review focused specifically on exercise as a
treatment for fibromyalgia. This Cochrane review included
exercise trials conducted between 1966 and 2001 that were
defined as high quality training studies, which met
methodological quality criteria and included an exercise
dosage that was consistent with the American College of
Sport Medicine (ACSM) guidelines for healthy individuals
[111]. For aerobic training, the ACSM guidelines indicate that
the frequency of exercise is required to be at least 2 days per
week at an intensity to achieve 40% to 85% of heart rate
reserve or 55% to 90% predicted maximum heart rate. In
addition, the duration of exercise must be at least 20 minutes
duration (range 20 to 60 minutes), either as continuous
exercise or spread intermittently throughout the day, and
using any mode of aerobic exercise for a total time period of
at least 6 weeks. The review identified 16 randomized clinical
trials that evaluated the effects of 23 exercise interventions in
fibromyalgia. Thirteen of these studies were judged to have
moderate to high methodological quality, eight of which also
met ACSM training guidelines. Among the latter eight
studies, aerobic training was evaluated in four trials [107,
112-114], strength training in one [115], mixed exercise in
one [106], and two trials included composite interventions of
biofeedback plus aerobic training [114] or education plus
aerobic training [116]. Modes of aerobic exercise that were
studied included cycle ergometry [112], aerobic dance [113],
whole body aerobics [107], and walking indoors [114]. A
meta-analysis of the four trials of aerobic exercise showed
that, compared to controls, those in the aerobic exercise
groups experienced significant short-term improvements in
cardiovascular fitness and tender points. However, the effect
of aerobic exercise on pain was not significant.
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following conclusions. First, large improvements with exercise
were seen for global well being, and moderate to large
effects on self-reported physical function. Second, the effects
of aerobic training on pain, fatigue, and sleep were weak and
inconsistent. Third, there was no evidence that aerobic
training improved psychological function. Fourth, it is unclear
from the data whether mixed regimens of different exercises
provided additional benefit beyond a single type of exercise.
Fifth, there was evidence in one study to support the use of
strength training, which improved pain, musculoskeletal
performance and psychological function, but more study was
recommended. Finally, only three of the studies examined
long-term effects of the exercise intervention. Improvements
in self-reported physical function and self-efficacy for function
were seen at one year follow-up in one study [114], but
another study found that, 4.5 years after the exercise
intervention, improvements were not retained in the exercise
group, although most were no longer exercising [107]. Lastly,
an uncontrolled three and six month follow-up of participants
in a program that included aerobic pool exercise and
education found that participants reported significant
improvements in the six minute walk test, fatigue, and self-
efficacy [116].
Recent non-pharmacological treatment studies of
fibromyalgia
Exercise
Exercise continues to be an active area of research in
fibromyalgia treatment. Since 2001, several trials have been
published that expand on the results of the earlier studies
reviewed in the aforementioned systematic analysis, which
focused on exercise that met ACSM guidelines for healthy
individuals. Recent trials have attempted to assess other
levels of exercise intensity, other forms of exercise, or
exercise in combination with other non-pharmacological
therapies for fibromyalgia.
Exercise intensity
A recent study of 143 women with fibromyalgia compared
24 weeks of mixed physical fitness training or biofeedback
with usual medical care [117]. The fitness protocol was
based on the ACSM guidelines and consisted of twice
weekly supervised group exercise of 60 minutes duration in
which patients performed aerobic exercise, stretching,
flexibility and balance exercises, and isometric muscle
strengthening; an additional third unsupervised weekly
exercise session was also encouraged. The training intensity
was left up to each individual, based on the patient’s
experience of pain or fatigue. The biofeedback training
comprised individual 30 minute sessions twice weekly during
8 weeks with progressive relaxation practice using an audio
tape twice daily at home; patients were instructed to continue
twice daily relaxation exercises during the remaining 16 weeks
of the study. Among the 118 participants who completed the
study, no intervention led to significant or clinically relevant
improvement in pain, patient global assessment of well being,
functional ability, or psychological distress. Physical fitness
actually worsened during the trial in all groups. Notably, in
terms of training intensity and maximal heart rates achieved, the
fitness intervention was actually low impact training despite
efforts to encourage patients to follow a high impact version.
To assess the impact of exercise intensity on fibromyalgia
symptoms, another study randomly assigned 37 women with
fibromyalgia to either a high intensity aerobic fitness training
regimen or a low intensity aerobic fitness training regimen
[118]. The high intensity group had supervised exercise
3 times weekly for 60 minutes over 20 weeks, adapting the
protocol used by McCain and colleagues [112]. The low
intensity protocol consisted of twice weekly supervised
exercise for 60 minutes for 20 weeks; an additional third, un-
supervised 60 minute weekly session was also encouraged.
The low intensity protocol was designed to meet ACSM
guidelines for the development and maintenance of
cardiorespiratory and muscular fitness. However, the training
intensity was left up to each subject, who could stop or
interrupt exercise as needed for pain or fatigue. The primary
outcome was the patient global assessment of well being.
The results indicated that neither intervention led to
substantial improvement between baseline and 20 weeks.
The most important change was a 20% increase in pain in
the high intensity group. Furthermore, there was no significant
difference between the high intensity and low intensity
training in the improvement in physical fitness. Notably, about
50% of the subjects in both groups were unable to fully
comply with the training sessions. By contrast, patients in the
cardiovascular training group in the McCain and colleagues
study [112] had better compliance and achieved a higher
fitness level. However, this study included only those patients
who could complete a treadmill exercise stress test, which
may have selected for a more physically fit patient subgroup.
In an attempt to assess the effects of graded aerobic exercise
in a more generalizable group of patients with fibromyalgia, a
randomized, controlled trial evaluated a community-based
exercise program in 132 patients with fibromyalgia that
included all patients seen in an outpatient rheumatology clinic
[119]. The patients were randomly assigned in equal
proportions to either graded aerobic exercise or relaxation
twice weekly for 12 weeks. The aerobic exercise group was
given an individualized program of gradually increasing
intensity, as tolerated, of either walking on a treadmill or
cycling on an exercise bicycle. By the end of the 12 weeks
the patients were doing two sessions of 25 minutes each of
exercise at an intensity that made them sweat while allowing
them to talk comfortably. The relaxation and flexibility group
performed upper and lower limb stretches and practiced
relaxation techniques for an hour twice weekly for 12 weeks.
Both groups received information about fibromyalgia and
were advised that exercise could improve their condition. The
primary outcome was the change in self-rated global
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significantly more patients in the exercise arm 24/69 (35%)
were much better or very much better compared with the
relaxation arm 12/67 (18%). At 12 months follow-up, the
benefits were maintained in 26 (38%) and 15 (22%) of the
participants, respectively (not significant). Furthermore,
significantly more patients in the exercise group experienced
a decrease in tender point counts at the 12 months follow-up.
Although this study was adequately powered with a diverse
group of fibromyalgia patients, involved a sufficient control
group, and included a 1 year follow-up, the study was limited
by compliance problems in that only 53% of the total group
attended over one-third of the classes.
Compliance for exercise programs was addressed in another
study that assessed whether a home-based, video-based,
low-impact aerobic exercise program would improve physical
function and symptoms of fibromyalgia [120]. In addition, the
study compared the efficacy of one long exercise bout with
two short exercise bouts per training day on physical function,
fibromyalgia symptoms, and exercise adherence. A total of
143 women with fibromyalgia were randomly assigned to
either a group that used a long bout of exercise, a group that
used short bouts of exercise, or a group that performed no
exercise. The 16 week, low-impact aerobics, videotaped
program consisted of warm-up and cool-down segments and
a training portion with rhythmic movements of all major
muscle groups of the lower extremities, but minimal
involvement of the upper extremities. The long bout of
exercise program was to be performed once daily; the
training segment progressed from 10 minutes per session to
30 minutes per session by week 9. The short bouts of
exercise program was to be performed during two sessions
per day separated by at least four hours. The short bouts of
exercise training session began at 5 minutes per session and
progressed to 15 minutes per session by week 9. Exercise
intensity for both programs was modulated through the use of
heart rate and rating of perceived exertion. Participants also
attended monthly meetings in which they received instruction
on how to monitor exercise intensity and to address problems
related to the exercise program. The group leader also called
each participant every four weeks to provide encouragement
and to help with problem solving related to exercise
difficulties. Both exercise groups were given an exercise and
daily symptoms logbook. The control no-exercise group
attended monthly group discussion sessions without
educational information and received calls every four weeks
for an assessment of their status. They were also asked to
record symptoms in a daily log. After 16 weeks, there were
no differences between the exercise groups and the no-
exercise group for symptoms, disease severity, pain, self-
efficacy, or psychological well-being. There were high attrition
rates for both exercise groups and minimal changes in fitness
levels. The authors concluded that a home-based, video-
taped-based, low impact aerobic exercise is not an ideal
combination of mode and method for delivery of exercise
programs for individuals with fibromyalgia and that a
supervised exercise program may be preferable. Furthermore,
the fractionation of exercise did not enhance exercise
adherence or minimize attrition.
By contrast, a 12 week, home-based, moderate intensity
exercise program for fibromyalgia that included 4 sessions
with an exercise physiologist who provided an individualized
exercise prescription based on the ACSM guidelines for
developing and maintaining cardiorespiratory fitness was
effective in improving health status, especially for women who
were more functionally disabled [121]. Notably, cardio-
vascular fitness levels did not change for patients, despite
improvement in functional ability. However, this study did not
include an attention-control group, making it difficult to
assess the effects of subject expectancy on the results.
The relationship between cardiovascular fitness and symptom
change was explored further in a recent, randomized,
controlled, 20 week study comparing aerobic fitness training
and stretching exercises in 76 sedentary women with fibro-
myalgia [122]. Sixty women completed the twenty week trial
and were included in the analysis. Unlike most previous
exercise studies in fibromyalgia, all patients in this trial were
newly diagnosed and had never had previous treatment. In
addition, only acetaminophen was allowed as rescue
medication during the trial. The aerobic group exercise
consisted of walking that was monitored with frequency
meters and supervised by a physiotherapist 3 times a week
for 45 minutes duration. The group stretching program
consisted of 3 sessions a week for 45 minutes duration and
included 17 exercises using muscles and joints without
increasing heart rate. Although aerobic exercise was
significantly superior to stretching in improvement of pain,
quality of life and psychological status, there was no
association between gains in cardiovascular fitness and
these improvements.
Exercise in combination with other interventions
Education in combination with exercise was explored in two
recent trials. One study was a 6 and 24 month follow up of
participants in a previous study that examined the effects of
6 months of pool exercises combined with a 6 session
education program in 69 women with fibromyalgia. The
program included 35 minutes of exercise in a temperate pool,
supervised by a physical therapist, once a week for 6 months
in groups of 6 to 10 patients. Patients were encouraged to
modify the exercises individually for pain or fatigue, and the
exercise was not designed to elicit a training effect. The
education program, which consisted of six one-hour sessions
led by a physical therapist, included education about factors
contributing to chronic pain, strategies to cope with fibro-
myalgia symptoms and stress, instruction and practice of
relaxation techniques, and encouragement to increase
physical activity. Only the 58 patients who completed the
trial, including 28 in the treatment group and 30 in the no-
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total Fibromyalgia Impact Questionnaire score improved
significantly more in the treatment group compared with the
control group. However, because the control was a no-
treatment group, it is difficult to assess the effect of therapist
attention or patient expectancy on the results. Furthermore, it
is not possible to determine whether the combination of
education and exercise was superior to either intervention
alone [123]. In the 6 and 24 month uncontrolled follow-up
study, 26 members of the original treatment group were
assessed and most reported regular physical activity but only
a few continued pool exercises. The patients reported that
the symptoms of fibromyalgia, including pain and fatigue,
were improved 30 months after the baseline, although the
scores still indicated moderate to severe symptoms.
Furthermore, the total Fibromyalgia Impact Questionnaire
score was not significantly improved compared to baseline
[124]. Another study that examined the efficacy of a six week
program of supervised pool exercises and education
compared to a waiting list control found that the patients in
the treatment group had significantly more improvement in
quality of life, functional consequences of fibromyalgia, and
patient satisfaction compared to the waiting list control group
[125]. However, as noted above, limitations in the study
design, including the no-treatment control group and the lack
of comparison groups of exercise or education alone, make it
difficult to determine which elements of the intervention
contributed to the encouraging results.
The effects of exercise and education were separately
evaluated in a 12 week study of a supervised aerobic exercise
program, a self-management education program, and the
combination of exercise and education in 152 women with
fibromyalgia [126]. The exercise, which was a supervised
program that met 3 times a week, for an average duration of
20 to 40 minutes, was based on the ACSM recommen-
dations for maintaining and developing cardiorespiratory
fitness in healthy adults, monitored with heart rate and ratings
of perceived exertion, and included walking, pool exercise or
low impact aerobics. However, patients were instructed to
begin at a comfortable level and to strive to increase the
intensity and duration to meet the ACSM guidelines. The
education group, based on principles of self-management,
met once a week for one-and-a-half to two hours per session.
A control group was given written instructions for basic
stretches and general coping strategies, and they were
contacted once or twice to ensure that they were completing
a logbook that documented the course of fibromyalgia and
weekly goals (also given to treatment groups) and answer any
questions about their condition. Only when compliance was
taken into account did any significant differences arise in the
groups. For patients who complied with the protocol (only
about half of the total group), the combination of supervised
exercise and group education improved self-efficacy for
coping with some symptoms compared with the control
group, although this significant difference was lost at the six
month follow-up evaluation. The high drop out rate indicated
that patients with fibromyalgia may have difficulty complying
with treatments that involve exercise and behavior modification.
Muscle strengthening exercises
Two recent studies evaluated the effectiveness of muscle
strength training in women with fibromyalgia. The first study
of 68 women compared a 12 week, twice weekly 60 minute
exercise program consisting of either muscle strengthening
or stretching [127]. The muscle strengthening group received
a supervised, classroom based, progressive non-aerobic
training program that minimized eccentric work. The control
flexibility training group received a classroom-based
supervised program with stretching that targeted the same
muscle groups as the strengthening group. Both groups
experienced increased strength and flexibility, but there were
no significant differences between the treatment and control
groups at the end of testing in the 56 patients (28 in each
group) who completed the study. Another study examined the
effect of a 12 week, twice weekly, 30 minute, strength training
program that worked the major muscle groups in 29 women
with fibromyalgia [128]. Although there were significant
improvements in strength and upper body functionality
compared to a waiting list control, tender point sensitivity and
fibromyalgia impact did not change. The results were also
limited by the small sample size and high attrition rate in the
strength group (47% did not complete the study).
Maintenance of exercise
Long-term adherence with exercise programs after completion
of studies has been consistently low in the studies of
fibromyalgia. Recent studies have attempted to identify
predictors of exercise maintenance in patients with fibro-
myalgia in order to address the problem of adherence. A
follow-up study of 39 women with fibromyalgia who had been
randomized to an individualized, home-based exercise
program of stretching and aerobics found that worse
maintenance of stretching at 3 months was associated with
high stress at baseline and increase in stress during the
treatment. Disability at baseline, increases in barriers to
exercise and upper-body pain during treatment were
associated with worse maintenance of aerobic exercise.
Therefore, maintenance of exercise in this group of women
with fibromyalgia was contingent on being able to deal with
stress, pain, barriers to exercise, and disability [129]. Another
study of 444 patients with fibromyalgia found that having a
higher exercise self-efficacy (i.e., confidence in the ability to
exercise under adverse conditions), lower depression, and
larger social support network predicted continued exercise.
Interventions that address exercise self-efficacy, depression,
and social support are needed to improve exercise
participation [130].
Cognitive-behavioral therapy
The results of the aforementioned systematic reviews
suggest that cognitive behavioral therapy (CBT) was no
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fibromyalgia. Since 2000, there have been other randomized,
controlled studies that further explored the possible use of
CBT in fibromyalgia. In the first study, 145 patients with
fibromyalgia were randomized to either standard medical care
that included pharmacological treatment and suggestions for
aerobic fitness or the same standard medical treatment and
the addition of six group cognitive behavioral therapy
sessions over a four week period that were specifically aimed
at improving physical function [131]. The CBT focused on
instruction and practice of nine skills, including the relaxation
response, visual imagery techniques, pacing skills, pleasant
activity scheduling, communication and assertiveness
training, cognitive restructuring principles, stress manage-
ment, and problem solving. Patients in both groups were
contacted monthly by phone to track health care use and
CBT skills in those assigned to CBT. Significantly more
(25%) of the 62 patients who completed the CBT protocol
achieved a clinically meaningful and sustained improvement
in physical functional status as measured by the physical
component summary score of the SF-36 compared with the
control group (12% of 60 completers). However, there were
no significant differences between the control and CBT
groups in change in sensory or affective pain scores as
measured by the McGill Pain Questionnaire. Although the
study was limited by the lack of monitoring of medication use
in the two groups, the lack of an attention-placebo group, and
the low level of adherence to CBT treatment (only 15% of
patients consistently reached their stated monthly CBT
goals), the study provided some evidence that targeted, brief,
group CBT, in conjunction with standard medical care, might
improve physical function in some patients with fibromyalgia.
A coping skills training (CST) intervention for adolescents
with fibromyalgia was developed to include developmentally
appropriate explanation and training guidelines as well as a
parent training component [132]. The content, similar to adult
CBT, included relaxation training, distraction techniques,
calming statements, activity pacing, pleasant activity
scheduling, and problem solving. Parents were given
suggestions for encouraging the adolescent to manage their
pain independently, maintain their normal day to day routines
and guidance for reducing avoidance of school or social
activities. In an 8 week study of this intervention added to
standard medical care that was stabilized for at least 4 weeks
prior to enrollment, 30 adolescents with fibromyalgia were
randomly assigned to either CST or a self-monitoring
condition in which patients monitored daily symptoms without
instruction about behavioral change. After 8 weeks, patients
were crossed over into the opposite treatment arm for an
additional 8 weeks. At the end of 8 and 16 weeks, there were
no significant differences in function disability or depressive
symptoms between the CST and self-monitoring groups.
However, the CST group showed significantly greater
improvement than the control group for increase in pain-
coping efficacy. These results are consistent with adult
studies of CBT in which there have been inconsistent effects
of CBT on pain reduction, although there have been improve-
ments in function and the perception of control over pain.
Finally, CBT developed for the treatment of insomnia in
patients with fibromyalgia was tested in 47 patients who were
randomized to receive 6 weekly sessions of CBT, a control
behavioral therapy (sleep hygiene education), or usual care
(all patients continued any ongoing medical care) [133].
Patients receiving CBT achieved about 50% reduction in
nocturnal wake time, compared with the sleep hygiene
education group (20%) and the usual care group (3.5%).
Both CBT and the sleep hygiene education showed benefits
over usual care for reducing global insomnia symptoms, and
for improving mental well-being and mood. However, only the
sleep hygiene group reported significant improvement in pain
compared with the usual care group. Therefore, sleep
hygiene education and CBT may benefit fibromyalgia patients
with chronic insomnia, but further study is needed with larger
samples and greater experimental control through standard-
ization of other medical treatment [133].
Other non-pharmacological therapies
A group treatment with a combination of mindfulness
meditation and Qigong movement therapy was tested in 128
patients with fibromyalgia who were randomly assigned to
either an 8 week course of this multimodal mind-body
intervention or a control education support group. At the end
of 8, 16, and 24 weeks, there were no significant differences
between groups in change in pain, tenderness, walking,
mood, or impact of fibromyalgia [134].
Another study evaluated social support as a primary
intervention in patients with fibromyalgia [135]. In this study,
600 patients with fibromyalgia were randomized to either a
social support group, a social support and education group,
or a no-treatment control group that participated in assess-
ment interviews only. The experimental groups met for 10,
2-hour weekly meetings followed by 10 monthly meetings. At
the end of one year, there were no significant differences in
reductions of health care costs for the groups. There were
also no significant differences between groups in improve-
ment in depression, self-efficacy, fibromyalgia impact, or fibro-
myalgia knowledge. The social support and education group
reported significantly less helplessness compared with the
other groups. Notably, attendance rates for the interventions
were low, with experimental groups attending only about
40% of all meetings.
Complementary and alternative medicine
A 2003 review of studies conducted between 1975 and
2002 evaluating the use of complementary and alternative
medicine in fibromyalgia concluded that, across the five
classifications of complementary and alternative medicine,
including alternative medical systems (e.g., acupuncture,
homeopathy), biological-based therapy (e.g., nutritional
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magnetic therapy), and manipulative and body-based systems
(e.g., chiropractic care, massage), and mind-body inter-
ventions (e.g., relaxation, biofeedback, and hypnotherapy), no
single modality was consistently effective [136]. Acupuncture
had the strongest evidence for effectiveness while there was
moderate evidence supporting the use of magnesium supple-
mentation, S-adenosyl-L-methionine, and massage therapy.
However, two recent, randomized, controlled trials found that
acupuncture was no better than control interventions in
reduction of pain associated with fibromyalgia. The first study
randomized 114 patients with fibromyalgia to either traditional
needle placement with or without needle stimulation or to
control groups of non-traditional needle location with or
without needle stimulation [137]. All patients received a total
of 18 treatments beginning once weekly, followed by twice
weekly, and finally three times weekly. Clinically meaningful
treatment response, defined by a 30% improvement in pain,
occurred in 25% to 35% of all patients; there were no
significant differences between groups on improvement in
pain. These results suggest that there are no specific effects
of acupuncture on pain reduction in patients with fibromyalgia.
A second study of acupuncture in fibromyalgia randomized
100 patients with fibromyalgia to 12 weeks of twice weekly
acupuncture that was specifically designed to treat fibro-
myalgia, or 1 of 3 sham acupuncture treatments: acupuncture
for an unrelated condition; needle insertion at non-acupoint
locations; or non-insertive simulated acupuncture using a
toothpick to mimic needle insertion [138]. The mean pain
ratings among patients receiving acupuncture did not differ
from that in the pooled sham acupuncture group. Therefore,
consistent with the previous study, acupuncture was no
better than sham treatment at relieving pain in fibromyalgia.
Limitations of non-pharmacological treatment studies
in fibromyalgia
Non-pharmacological treatment studies of fibromyalgia are
limited for several reasons [111,118,139]. First, there was
variability in accounting or controlling for other interventions,
particularly pharmacological treatment, making it difficult to
isolate the effects of the non-pharmacological treatment on
fibromyalgia. Second, there was also variability in the treat-
ment intensity, duration, and frequency, making it difficult to
identify the best treatment levels for patients with fibro-
myalgia. Third, diversity of treatment modalities limited
comparisons between studies. For example, training
modalities in exercise studies have included cycling, pool
exercise, walking, muscle strength exercises, stretching, and
others. The diversity of treatment elements was also evident
in CBT studies, which varied in the skill sets that were taught
and format of treatment (e.g., group or individual). Fourth,
patient selection criteria in exercise studies have not
consistently taken into account the baseline level of physical
activity or fitness and the potential impact of these variables
on the results. In addition, few studies identified comorbid
mood or anxiety disorders, which may have affected the
patients’ response to treatment. Notably, patients with severe
depression may not respond well to some non-pharmaco-
logical treatments, such as education and physical training
[104]. The studies have not yet clarified which subgroups of
patients with fibromyalgia might benefit from a specific mode
of non-pharmacological treatment. Fifth, many studies had
small sample sizes and high attrition rates in the treatment
groups, making it difficult to identify benefits of the treatment.
Indeed, adherence to CBT skills over an extended period of
time has been problematic in studies of fibromyalgia [131].
Adherence with exercise programs, especially after the
completion of the intervention, was also generally low.
Furthermore, there was some discrepancy in several exercise
studies between the prescribed exercise program and the
actual performed exercise because of problems with patient
tolerability. Furthermore, there was inconsistent reporting of
specific adverse events from exercise such as exacerbation
of pain. Sixth, several studies had no-treatment controls,
which made it difficult to distinguish the specific effects of the
treatment from the non-specific effects of attention or group
experience or the role of subject expectancy on the results.
Indeed, CBT studies that used attention or education
controls found that CBT-supported skills added little to the
outcome of the studies [105,108]. Seventh, although some
studies followed patients for more than one year after the
intervention, most studies focused on short-term benefits of
treatment in fibromyalgia, which is a chronic disorder. Eighth,
as in pharmacological clinical trials of fibromyalgia, there was
a lack of consensus about important symptom domains and
outcome measures, making comparisons between studies
difficult. Furthermore, it was unclear from some studies
whether significant changes were actually clinically meaning-
ful. In exercise studies, there were also multiple approaches
to the assessment of aerobic capacity and performance.
Furthermore, other health outcomes that might be affected by
exercise, such as blood pressure, weight, or metabolic
indicators have not been consistently tracked in exercise
studies.
Summary of non-pharmacological trials in fibromyalgia
Although more research is needed to address the
aforementioned limitations, the available evidence supports
the conclusions summarized in Tables 3 and 4.
Conclusions and recommendations for the
treatment of fibromyalgia
The rapid growth of trials in fibromyalgia in recent years has
resulted in new, evidence-based approaches to treatment.
The American Pain Society (APS) developed guidelines for
the optimal treatment of fibromyalgia, a summary of which
was published in 2004 [140]. With the subsequent
publication of new treatment data reviewed above, some
updates to these guidelines may be necessary. The first
recommended steps of the APS guidelines, which included
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and evaluation and treatment of comorbid disorders, such as
mood and sleep disturbances, are still appropriate. However,
the subsequent steps do not take the presence of
comorbidity into account when recommending treatment for
fibromyalgia. Recent evidence suggests that comorbidity and
the presence and severity of symptom domains should be an
important consideration when selecting initial treatments for
fibromyalgia. In the APS guidelines, the first recommended
pharmacological treatment is a trial of low dose tricyclic
antidepressants or cyclobenzaprine. However, these medica-
tions are often poorly tolerated and, at low doses, are not
effective for the treatment of mood or anxiety disorders, two
common comorbid conditions. An alternative approach would
be to recommend one of the new selective SNRIs as a first
line treatment for pain in patients with or without depression
or anxiety. One caveat related to the use of SNRIs or other
medications with antidepressant effects in fibromyalgia is that
they should not be used as monotherapy in patients with
bipolar disorder, another frequently reported comorbid
condition [141], because of the risk of increased mood
instability. An alternative first line medication approach is an
alpha 2 delta ligand, which may be particularly helpful in
patients with prominent sleep disturbances or anxiety. For
those patients who do not respond completely to mono-
therapy with either an SNRI or an alpha 2 delta ligand, a
combination of these medications should be considered,
although studies of this and other combination pharmaco-
therapy is still very limited [142].
In the APS guidelines, exercise was recommended early in
treatment of fibromyalgia. However, recent studies indicate
that the compliance with exercise is quite low and influenced
by factors such as pain severity, stress, disability, depression,
self-efficacy, social support, and barriers to exercise.
Therefore, these issues should be addressed before recom-
mending exercise. Studies suggest that exercise does not
consistently improve major symptom domains such as pain,
fatigue, sleep disturbance, or psychological symptoms.
Patients with these symptoms may not be able to tolerate
exercise and may in fact experience a worsening of pain with
exercise. Consequently, these symptoms should be treated
with medication (or other therapy as described below) first to
increase the likelihood that the patients will be able to
participate in exercise and benefit from the positive impact of
exercise on cardiovascular fitness, pain pressure thresholds,
global well being, and self-reported physical function. The
patient’s level of fitness should also be considered when
suggesting specific exercises. For most patients, a gradual
increase, as tolerated, in exercise to reach a goal of 30 to
60 minutes of low-moderate intensity aerobic exercise (e.g.,
walking, pool exercises, stationary bike) at least 2 to 3 times a
week is best tolerated. Furthermore, studies suggest that
supervised, group exercise interventions may be preferable to
home-based exercise regimens, especially at the initiation of
an exercise program.
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Table 3
Summary of findings from exercise studies in fibromyalgia
1. Among exercise interventions, the evidence is most supportive of
aerobic exercise in the treatment of fibromyalgia.
2. Aerobic exercise does not consistently improve major symptom
domains associated with fibromyalgia, including pain, fatigue,
sleep disturbance, or psychological symptoms.
3. Patients who tolerate and comply with a high level of aerobic
exercise intensity that meets the American College of Sport
Medicine guidelines for cardiovascular endurance demonstrate
improvements in cardiovascular fitness, pain pressure thresholds,
global well being, and self-reported physical function.
4. Many patients do not tolerate high intensity aerobic exercise with
reports of increased pain following this intervention.
5. Low to moderate intensity, graded aerobic exercise (e.g., walking
or cycling on a stationary bicycle) may lead to improvements in
global assessments, tender points, and quality of life.
6. Improvements in fibromyalgia with exercise may occur without
change in cardiovascular fitness levels, and the mechanisms by
which exercise improves fibromyalgia are unclear.
7. Although optimal intensity, duration, and frequency of exercise
have not clearly been established, studies to date suggest that, for
many patients, a gradual increase, as tolerated, in exercise to
reach a goal of 30 to 60 minutes of low-moderate intensity aerobic
exercise (e.g., walking, pool exercises, stationary bike) at least 2 to
3 times a week for more than 10 weeks appears to be associated
with positive short-term benefits. Ongoing exercise is associated
with maintenance of improvements in fibromyalgia.
8. Supervised, group exercise interventions may be preferable to
home-based exercise regimens, especially at the initiation of an
exercise program.
9. Adherence to exercise is problematic for many patients with
fibromyalgia. Factors that contribute to low adherence to exercise
include disability, stress, exacerbation of pain, depression, low
exercise self-efficacy (i.e., low confidence in the ability to exercise
under adverse conditions), barriers to exercise, and low social
support.
Table 4
Summary of findings from cognitive and behavioral therapies,
education, and complementary and alternative medicine
1. Cognitive skills training in general has not shown more benefit than
group education or social support in improving fibromyalgia.
2. CBT that is targeted to specific outcomes such as function, sleep,
or coping may be beneficial for fibromyalgia.
3. Group education with social support can reduce pain behaviors
and feelings of helplessness.
4. Combining education with exercise can improve a sense of control
over symptoms and reduce the impact of fibromyalgia.
5. As in exercise studies, adherence to psychological and education
programs is problematic, emphasizing the need to identify
subgroups of patients who might benefit from these programs. For
example, patients with severe depression may not be candidates
for this approach until the depression is treated.
6. Traditional acupuncture did not reduce pain associated with
fibromyalgia more than sham interventions.
7. Convincing evidence does not exist for complementary and
alternative medicine in the treatment of fibromyalgia.Some patients who do not respond fully to medication alone
or have prominent psychosocial problems might benefit from
the addition of CBT or group education as an adjunct to their
medical treatment. Group education with social support may
help to reduce pain behaviors, feelings of helplessness,
improve a sense of control over symptoms, and reduce the
impact of fibromyalgia. CBT that addresses disability, function,
or self-efficacy might also be helpful in overcoming some of
the barriers to exercise, improving overall function, and
regaining a sense of control in their lives. Combinations of
exercise and education or CBT may be an option for patients
who do not respond to a single approach, but more study of
combination therapies is needed.
Table 5 summarizes the new approach to the stepwise
treatment of fibromyalgia.
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Table 5
Stepwise treatment of fibromyalgia
Step 1
Confirm diagnosis
Identify important symptom domains and their severity (e.g., pain,
sleep disturbance, fatigue) and level of function
Evaluate for comorbid medical and psychiatric disorders (e.g.,
sleep apnea, osteoarthritis, depressive or anxiety disorders); may
require referral to specialist
Assess psychosocial stressors, level of fitness, barriers to
treatment
Provide education about fibromyalgia (individual or group)
Review treatment options
Step 2
Recommend treatment based on the results of the individual evaluation
For patients with moderate to severe pain, trial with medication as
a first line approach:
With or without lifetime depression or anxiety: trial of selective
serotonin and norepinephrine reuptake inhibitor (not
recommended as monotherapy for patients with comorbid
bipolar disorder)
Prominent sleep disturbance or anxiety: trial of alpha 2 delta
ligand
Partial response to monotherapy with either selective
serotonin and norepinephrine reuptake inhibitor or alpha 2
delta ligand: trial of combination of these agents
Consider other medications if no response to the above
approach (e.g., selective serotonin reuptake inhibitor (SSRI);
tricyclic antidepressant (TCA); combination of SSRI with low
dose TCA (watch for drug interaction between SSRI and
TCA); combination of SSRI and alpha 2 delta ligand)
Avoid drugs with high likelihood of abuse or dependence
Provide any additional treatment for comorbid conditions (e.g.,
non-steroidal anti-inflammatory drugs for osteoarthritis, continuous
positive airway pressure for sleep apnea)
Step 3
Adjunctive CBT for patients with prominent psychosocial stressors, or
difficulty coping or functioning
Exercise prescribed according to fitness level (e.g., goal of 30 to
60 minutes of low-moderate intensity aerobic exercise (e.g., walking,
pool exercises, stationary bike) at least 2 to 3 times a week).
Encourage participation in supervised or group exercise.
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